Pharma deals under a microscope at FTC

In our weekly expert view piece, John Maloney and Eleanor Tyler, from Bloomberg Law analyze the reasons behind Federal Trade Commission's increased scrutiny on pharma deals.

Pharmaceuticals deals are being challenged at a much higher rate than other mergers reported to the U.S. Federal Trade Commission (FTC), according to an analysis of data from the FTC and Bloomberg BNA's Deal Analytics.

Ultimately, however, the analysis shows that deals have been approved with a consent order—rather than blocked by regulators—in challenged cases.